Published in Cell Reports Medicine · View the paper (DOI)
A new study provides preliminary evidence that an existing drug, α-difluoromethylornithine (DFMO), could be used to treat type 1 diabetes. The drug has already been FDA-approved for other indications and may offer a more convenient treatment option for patients.
Coverage from 2 institutions